The American Journal of Medicine
Volume 123, Issue 6 , Pages 489-495 , June 2010

Caring for the Breast Cancer Survivor: A Guide for Primary Care Physicians

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96
  2. American Cancer Society. Cancer facts and figures 2008. http://www.cancer.org/docroot/STT/STT_0.aspAccessed May 20, 2009
  3. National Cancer Institute Office of Cancer Survivorship. Estimated US cancer prevalence counts: who are cancer survivors in the US?. http://dccps.nci.nih.gov/ocs/prevalence/index.htmlAccessed May 20, 2009
  4. Sakorafas GH, Peros G, Cataliotti L, Vlastos G. Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol. 2006;15(3):153–165
  5. Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27:390–397
  6. Petrek AJ, Cheville AL. Diseases of the breast. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004;
  7. Hurria A, Hudis C. Follow-up care of breast cancer survivors. Crit Rev Oncol Hematol. 2003;48(1):89–99
  8. Sener SF, Winchester DJ, Martz CH, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer. 2001;92(4):748–752
  9. National Lymphedema Network Medical Advisory Committee. Position Statement of the National Lymphedema Network: Topic: air travel. www.lymphnet.org/pdfdocs/nlnairtravel.pdfAccessed May 20, 2009
  10. Burnstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med. 2000;343(15):1086–1094
  11. Glynn C, Litherland J. Imaging breast augmentation and reconstruction. Br J Radiol. 2008;81:587–595
  12. Soo MS, Kornguth PJ, Hertzberg BS. Fat necrosis in the breast: sonographic features. Radiology. 1998;206(1):261–269
  13. Cooke AL, Metge C, Lix L, Prior HJ, Leslie WD. Tamoxifen use and osteoporotic fracture risk: a population-based analysis. J Clin Oncol. 2008;26(32):5227–5232
  14. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60–62
  15. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after 2 to 3 years of tamoxifen in post menopausal women with primary breast cancer. N Engl J Med. 2004;350:1081–1092
  16. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole after 5 years of tamoxifen in post menopausal women with early-stage breast cancer. N Engl J Med. 2003;349:1793–1802
  17. Goss PE, Ingle JN, Martino S, et al. Updated analysis of NCIC CTG MA.17 randomized placebo controlled trial of letrozole after 5 years of tamoxifen in post menopausal women with early stage breast cancer [abstract 847]. Proc Am Soc Clin Oncol. 2004;23:87
  18. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53
  19. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25:829–836
  20. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer. 2008;112(5):1001–1010
  21. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–691
  22. North American Menopause Society. The role of calcium in peri- and postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006;13:862–877
  23. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21(21):4042–4057
  24. Pérez-López FR, Chedraui P, Haya J. Vitamin D acquisition and breast cancer risk. Reprod Sci. 2009;16:7–19
  25. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist. 2008;13:1224–1234
  26. Patt DA, Goodwin JS, Kuo YF, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol. 2005;23(30):7475–7482
  27. Harris EE. Cardiac mortality and morbidity after breast cancer treatment. Cancer Control. 2008;15:120–129
  28. Buzdar AU, Marcus C, Smith TL, Blumenschein GR. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer. 1985;55:2761–2765
  29. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–983
  30. Seidman A, Hudis C, Perri ML, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–1221
  31. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. 2009;20:993–999
  32. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860–864
  33. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937–947
  34. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25(36):5715–5722
  35. Wasan KM, Goss PE, Pritchard PH, et al. The influence of letrazole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA 17L). Ann Oncol. 2005;16:707–715
  36. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BID 1-98. J Clin Oncol. 2007;25:486–492
  37. Ragaz J. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol. 1998;16:2018–2024
  38. Rossouw JE Anderson GL, Prentice RL, et al. ; Writing Group for the Women's Health Initiative Investigators (Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial). JAMA. 2002;288–321
  39. Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100:475–482
  40. Chalasani P, Downey L. Menopausal symptoms: alternatives to hormone replacement therapy (HRT). Ariz Geriatr Soc. 2008;13:9–13
  41. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113–121
  42. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–2746
  43. Klatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;24(31):5091–5096
  44. Rojas MP, Telaro E, Russo A, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database Syst Rev. 2005;225(1):CD001768
  45. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89
  46. National Cancer Institute. Breast cancer risk assessment tool. http://www.cancer.gov/bcrisktool/Accessed May 30, 2009
  47. Curtis RE, Boice JD, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med. 1992;326:1745–1751
  48. Praga C, Bergh J, Bliss J, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol. 2005;23:4179–4191
  49. Smith RE. Risk for the development of treatment-related leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer. 2003;4:273–279
  50. Averette HE, Mirhashemi R, Moffat FL. Pregnancy after breast carcinoma: the ultimate medical challenge. Cancer. 1999;85(11):2301–2304

 Funding: None.

 Conflict of Interest: Drs. Downey and Stopeck have received honoraria and clinical trial support from multiple pharmaceutical companies involved in breast cancer treatment, including Novartis and AstraZeneca.

 Authorship: All authors meet the criteria for authorship, including acceptance of responsibility for the scientific concept of the manuscript.

PII: S0002-9343(10)00127-0

doi: 10.1016/j.amjmed.2009.09.042

The American Journal of Medicine
Volume 123, Issue 6 , Pages 489-495 , June 2010

Article Tools

* Image Usage & Resolution